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Sickle cell disease (SCD) is a hereditary hemoglobinopathy that affects over 100,000 people in the United
States. Patients with SCD are known to experience suboptimal health-related quality of life (HRQoL). In
addition to the physical manifestations of SCD, psychological and social stress, along with academic difﬁ-
culties, secondary to the chronicity of the disease and its complications often affect patients with SCD.
Although medical therapy of SCD has improved, allogeneic hematopoietic cell transplantation (allo-HCT)
remains the only curative therapy. The objective of this study was to measure HRQoL before and after allo-
HCT by assessing physical, psychological, and social functioning in patients with SCD who have undergone
reduced-toxicity conditioning (busulfan/ﬂudarabine/alemtuzumab) followed by allo-HCT. Patients < 21 years
of age undergoing allo-HCT (matched siblings and unrelated donors) for SCD and their primary caregiver
were enrolled using either the English or Spanish version of the PedsQoL 4.0. Data were collected at 3 time
points: before allo-HCT and on days 180 and 365 after allo-HCT. The change in HRQoL from baseline was
assessed with unadjusted and adjusted mixed-effects models in which subjects were treated as random
effects, and variance component structure was used. Seventeen patients and 23 primary caregivers were
enrolled and reported a mean overall HRQoL of 66.05 (SD, 15.62) and 72.20 (SD, 15.50) at baseline, respec-
tively. In the patient-reported analysis with adjusted mixed-effects models, the estimated improvements in
overall HRQoL were 4.45 (SE, 4.98; P ¼ .380) and 16.58 (SE, 5.06; P ¼ .003) at 180 and 365 days, respectively,
after allo-HCT. For parent-reported overall HRQoL, the estimated improvements were 1.57 (SE, 4.82; P ¼ .747)
and 9.28 (SE, 4.62; P ¼ .053) at 180 and 365 days, respectively, after allo-HCT. Similar results were found
across the physical, social, and emotional HRQoL domains with mixed-effects models after adjustment of
demographic and medical variables. In addition to the alleviation of clinical manifestations of SCD, these
patients demonstrated signiﬁcant improvement in most aspects of HRQoL by 1 year after allo-HCT. These data
represent the trajectory of HRQoL during the initial year of follow-up within this population and should be
integrated into the decision-making process when considering allo-HCT in patients with SCD.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
As of 2011, 1000 children are born with sickle cell disease
(SCD) annually in the United States, with over 100,000
people living with the disease [1]. SCD is an hereditary he-
moglobinopathy that negatively impacts quality of life andedgments on page 672.
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ty for Blood and Marrow Transplantation.shortens life expectancy in affected individuals [2,3]. Physical
complications include painful vaso-occlusive crises (VOC),
stroke, acute chest syndrome, splenic sequestration, chronic
pulmonary and renal dysfunction, and avascular necrosis of
the joints [2,4-7]. In addition to the physical stress, psycho-
logical stress of the illness, including the chronicity of com-
plications, limitations in educational and recreational
activities due to symptoms, and ﬁnancial burdens experi-
enced by the family, are experienced by children and ado-
lescents [8]. Such childhood chronic illness can result in poor
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complaints, lower levels of school and social competence,
anxiety, and depression [8,9].
Supportive therapies have greatly improved for patients
with SCD, with therapeutic options including chronic blood
transfusions, hydroxyurea, and allogeneic hematopoietic
cell transplantation (allo-HCT). Recent advancements in the
research and application of allo-HCT for pediatric blood
disorders have led to increases in survivorship with eradi-
cation of SCD symptomatology. To date, allo-HCT is the only
established curative option in children with SCD [7]. There
are no guidelines as to when allo-HCT should be offered to
children with SCD, but historically, it has been reserved for
symptomatic patients, such as those with a history of stroke,
acute chest syndrome, or recurrent painful VOC, with HLA-
matched sibling donors (MSD) [2,7]. As outcomes for sibling
donor hematopoietic cell transplantation (HCT) have
improved, more children with SCD are being referred for
allo-HCT if they meet the deﬁnition of highly symptomatic
and have a suitably matched unrelated donor.
To our knowledge, there is only 1 published longitudinal
study that has investigated health-related quality of life
(HRQoL) in children with SCD after allo-HCT with observa-
tional follow-up of 1 year. Kelly et al. [10] compared HRQoL
reported by 13 parent-child dyads after allo-HCT for hemo-
globinopathies (SCD, 7 dyads; thalassemia, 6 dyads) to that of
parent-child dyads receiving allo-HCT for malignant diseases
or severe aplastic anemia. The patients in the hemoglobin-
opathy group reported higher HRQoL at baseline (physical
and emotional functioning scores) than those in the control
group and the majority of participants in both groups had
returned to baseline levels of functioning at 3 months after
transplantation, according to both parent and child report,
before essentially reaching a plateau. The 2 groups did not
differ in incidence of allo-HCTerelated complications (ie,
early infection, acute-graft-versus host disease [GVHD],
chronic GVHD) [11].
The present quality of life study is a secondary aim of a
medical treatment study that showed the efﬁcacy of a
reduced-toxicity conditioning (RTC) regimen in patients with
SCD undergoing allo-HCT using busulfan, ﬂudarabine, and
alemtuzumab [12]. An RTC is deﬁned as a regimen associated
with myeloablation but also associated with reduced toxicity
secondary to conditioning [13]. The medical treatment study
showed improvements in the physical manifestations of SCD
in those undergoing RTC allo-HCT. Patients had no VOC,
improvements in cardiac, pulmonary, and splenic function,
and stabilization of neurologic symptoms. This secondary
pilot study aimed to determine whether RTC allo-HCT
improved the emotional and social sequelae experienced
by many patients with SCD in addition to the physical
symptoms.METHODS
Participants
All patients younger than 21 years of age undergoing allo-HCT for SCD,
and their primary caregivers, were enrolled on this HRQoL study as part of
their medical treatment protocol to evaluate the efﬁcacy of an RTC regimen
followed by allo-HCT from related donors and unrelated cord blood donors
in patients with SCD. The protocol was approved by the institutional review
board and was in compliance with the Declaration of Helsinki. Informed
consent was signed before study initiation and HRQoL data were serially
collected as part of the medical protocol using the PedsQL 4.0 Generic Core
Scale for patients with SCD before and 1 year after allo-HCT.Treatment Plan
Twenty-three patients received a conditioning regimen consisting of
busulfan, ﬂudarabine, and alemtuzumab, and 1 patient received
melphalan, ﬂudarabine, and alemtuzumab as we have previously
described [12,14].
Medical Information
As part of the medical treatment study, demographic information, such
as indications for HCT, age at HCT, donor source, and conditioning regimen,
was collected. After allo-HCT, length of stay and readmissions during the
ﬁrst 100 days after allo-HCT were also recorded. Other assessments after
allo-HCT, such as engraftment, transfusion requirements, chimerism
studies, presence of GVHD, organ toxicity, and disease status were collected
using standard scoring scales [13,15-17].
Measures
HRQoL data were collected using the PedsQL 4.0 Generic Core Scale [18].
To assess all participants enrolled on the medical treatment study, this
follow-up study utilized 3 versions of the PedsQL 4.0: a self-report format
for children ages 5 to 18, a self-report format for young adults ages 18 to 25,
and a proxy report for parents of children ages 2 to 18. The scale contains 23
items that assess physical (8 items), social (5 items), psychological (5 items),
and school functioning (5 items). Overall HRQoL scores and psychosocial
health summary scores were calculated as well as 3 individual composite
scores (physical, social, and emotional functioning). It is important to note
that the school items were not included in the ﬁrst year analyses because
these patients are not allowed to return to school for 1 full year upon
completion of their allo-HCT. Consequently, overall HRQoL summary score is
a composite of the physical, emotional, and social functioning indices,
whereas the psychosocial HRQoL summary score is a composite of items
from the emotional and social functioning indices. Scores range from 0 to
100, with higher scores indicating higher HRQoL. Data for the present study
were collected from participants and their caregiver at 3 time points: before
transplantation and on days 180 and 365 (1 year) after allo-HCT. Participants
and their caregivers independently completed either the English or Spanish
version of the PedsQL 4.0 at each time point.
Statistical Analysis
Descriptive statistics were calculated for all demographic, medical, and
HRQoL variables. Speciﬁcally, the continuous variables were summarized by
mean, standard deviation, median, and range, and the categorical variables
were summarized by percentages. The change in HRQoL from baseline was
assessed with unadjusted and adjusted mixed-effects models. In the mixed-
effects model, the subjects were treated as random effects, and the variance
component structure was used. The variance component structure models a
different variance component for each random effect. The variables included
in the adjustedmixed-effects models were GVHD, insurance type, and donor
source. The estimated change of HRQoL from baseline was summarized with
mean and standard error (SE) along with its corresponding P value. The
relationship between proxy and patient HRQoL ratings was examined using
intraclass correlation coefﬁcients (ICC), an analysis that incorporates both
mean group differences and discrepancies across individual patient/parent
dyads, as well as Pearson’s product correlation coefﬁcients. The effect of the
baseline variables on themissingness of the overall HRQoL at each follow-up
time point was assessed with a logistic regression model. In mixed-effects
models, all subjects and data were included in the analyses, even if some
data were missing. A 2-sided P value less than .05 was considered as
signiﬁcant. The analysis was conducted in SAS 9.3 (Cary, NC).
RESULTS
Sample Baseline Characteristics
Seventeen patients and 23 proxies provided serial HRQoL
data. Mean age of participants was 8.97 years (SD, 5.28;
median, 7.3; range, 2.3 to 20.2). Of the 23 patients, 15 (65%)
had Hemoglobin SS (HbSS) disease, 4 (17%) had Hemoglobin
SC (HbSC) disease, and 4 (17%) had Hemoglobin Sickle Beta
Thalassemia (HbSbThal). Indications for HCT included acute
chest syndrome, recurrent VOC, dactylitis, splenic seques-
tration, retinopathy, and stroke (Table 1). Only 2 of the 23
patients had a history of stroke before HCT (1 with a silent
stroke and 1 with an overt stroke causing neurological
sequelae). Participants were predominantly male (n ¼ 19,
83%). The sample was racially divided as follows: Hispanic
(n ¼ 13, 56.5%), African American (n ¼ 9, 39.1%), and 1
Table 1
Patient Characteristics
ID Indications for HCT Age at
HCT, yr
Donor
Source
Initial HCT
LOS, d
% Whole Blood
Chimerism (Days
100, 180, 365
after HCT)
No. of
Transfusions
through Day
100 after HCT
(Platelet/PRBC)
GVHD Disease
Status
at 1 Year
No. of
Readmissions
in First 100
Days
after HCT
Post-HCT Complications Lansky/Karnofsky
Performance
Scores (Before
HCT, 1 Year
after HCT)
1 Dactylitis, ACS, VOC 5.3 RCB 78 95,97,94 17/10 No NED 1 None 90/no note
2 ACS 7.3 RBM 38 91,93,93 12/6 No NED 3 None 100/90
3 VOC 9.9 UCB 57 99,99,98 23/10 Yes-acute NED 2 None 100/90
4 VOC 5.3 RBM 43 98,96,93 6/1 No NED 0 None 100/90
5 VOC 7.0 RBM 42 90,88,80 0/0 No NED 1 None 100/100
6 Abnormal TCD, ACS 6.3 UCB 66 60,94,93 14/7 Yes-acute
and chronic
NED 0 Stroke 90/100
7 Splenic sequestration, dactylitis 2.7 RCB 105 65,88,89 43/14 No NED 4 None 100/no note
8 ACS 6.3 UCB 114 0, not evaluable,
not evaluable
95/19 Yes-acute NR 0 None 90/90
9 VOC, splenic sequestration 2.4 UCB 162 99,96,99 40/12 No NED 0 None 100/100
10 VOC, ACS 2.3 RBM 37 96,95,94 9/3 No NED 0 None 100/100
11 Sickle retinopathy, VOC, ACS,
splenic sequestration
18.3 RBM 37 99,96,94 3/3 No NED 1 None 100/90
12 VOC, ACS, splenic sequestration 9.4 RBM 57 92,94,78 31/10 Yes-acute NED 1 None 100/80
13 Abnormal TCD 5.4 RBM 44 89,79,75 15/8 No NED 1 None 100/100
14 Stroke, splenic sequestration 20.2 RBM 37 98,90,83 2/1 No NED 1 None 80/90
15 VOC, ACS 14.7 RBM 46 98,89,86 4/1 No NED 0 None 90/100
16 ACS, VOC 13.8 RBM 65 99,98,94 24/6 Yes-acute NED 1 None 100/no note
17 VOC 12.4 RBM 70 99,98,97 2/4 No NED 0 None 100/100
18 Splenic sequestration 4.5 UCB 57 85,91,91 19/11 No NED 1 None 100/no note
19 Splenic sequestration, ACS, VOC 16.3 RBM 30 99,98,92 1/4 No NED 1 None 100/100
20 Abnormal TCD, Silent stroke,
ACS, VOC
8.3 RBM 30 38,58,68 16/5 No NED 2 Stroke 100/100
21 ACS 12.4 RBM 29 89,87,93 2/1 No NED 0 PRES 100/100
22 ACS, splenic sequestration 13.3 RBM 55 99,83,77 11/7 No NED 0 Diarrhea, hypomagnesia,
grade II mucositis, E. Cloace
sepsis, Acinetobactor line
infection, VZV
100/80
23* Had no SCD-related
complications, had matched
sibling
2.7 Sibling
bone
marrow
40 100 16/7 No 0 Diarrhea, hypomagnesia,
grade II mucositis, E. Cloace
sepsis, Acinetobactor line
infection, VZV
100
LOS indicates length of stay; ACS, acute chest syndrome; RCB, related cord blood; NED, no evidence of disease; RBM, related bone marrow; UCB, unrelated cord blood; NR, no response; TCD, transcranial Doppler; PRES, posterior
reversible encephalopathic syndrome; VZV, varicella zoster virus.
* Patient not yet 1 year after HCT.
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divided closely by insurance type: Medicaid (n ¼ 10, 43.5%)
and private insurance (n ¼ 13, 56.5%). Source of hemato-
poietic cells was MSD bone marrow (n ¼ 16, 70%), MSD cord
blood (n ¼ 2, 9%), and unrelated cord blood (n ¼ 5, 21%).
Missingness
The total sample size is 23. Among the 23, self-reported
HRQoL was missing from 6 patients at baseline who were
too young for self report, from 3 patients at 180 days, and
from 6 patients at 365 days. In logistic regression of the
missingness as the outcome, none of the baseline charac-
teristics was signiﬁcant with P values > .10. Among the 23,
parent proxyereported HRQoL was not missing from any at
baseline, from 2 patients at day 180, and from 1 patient at
day 365. In logistic regression of the missingness of the
outcome, none of the baseline characteristics were signiﬁ-
cant with P values > .10. Therefore, the missingness is
considered at random and the missing values were ignored
in our data analysis.
Outcomes and Posteallo-HCT Complications
At 1 year after allo-HCT, overall survival was 100% and
event-free survival was 100%. The median follow-up was
1346 days, with a range from 364 days to 3306 days. Only 1
patient died, at day 420 after transplantation, and the others
were alive. Five patients (22%) developed GVHD and 18 pa-
tients (78%) did not. After allo-HCT, 1 patient developed a
hemorrhagic stroke in the setting of hypertension and as a
possible manifestation of a hemolytic reaction due to ABO
incompatibility immediately after transplantation, and
another developed a stroke 6months after transplantation in
the setting of uncontrolled hypertension. Follow-up mag-
netic resonance imaging (MRI) scans showed no progression
and no residual neurologic sequelae in either patient.
Another patient developed posterior reversible encephalo-
pathic syndrome, both clinically and radiographically on MRI
while receiving tacrolimus. After tacrolimus was dis-
continued, the symptoms resolved and the MRI normalized.
No cardiac or pulmonary dysfunction was observed in any
patient.
Overall HRQoL
Before allo-HCT, patients reported a mean overall HRQoL
of 66.05 (SD,15.62) (Table 2), which falls below the published
at-risk cutoff score (69.7) [19]. The mean HRQoL increased
steadily over time to 70.36 (SD, 13.24) at day 180 and 82.34
(SD, 13.86) at 1 year after allo-HCT. Similarly, parent proxies
reported a mean overall HRQoL at baseline of 72.20 (SD,
15.50) (Table 3), which increased consistently across timeTable 2
Self-Reported HRQoL Scores
Time Overall HRQoL Physical HRQoL
T1: Before HCT* (n ¼ 17 of 17, 100%) 66.05 (15.62) 62.61 (20.12) (n ¼ 16
T2: 180 Days* (n ¼ 16 of 17, 94%) 70.36 (13.24) 66.04 (17.67) (n ¼ 15
T3: 365 Days* (n ¼ 15 of 17, 88%) 82.34 (13.86) 79.79 (14.65)
Change over time
T2-T1y
Day 180-baseline
4.45 (4.98)
.380
3.23 (6.57)
.627
T3-T1y
Day 365-baseline
16.58 (5.06)
.003z
17.39 (6.58)
.015z
* Data presented are mean (SD). Result from adjusted mixed-effect model self-r
y Data presented are mean (SE); P value.
z Indicates statistical signiﬁcance.points to 73.82 (SD, 16.20) at day 180 and 81.92 (SD, 15.63) at
1 year after allo-HCT.
Results from the adjusted mixed-effect model for
patient-reported HRQoL total scores remained signiﬁcantly
higher than baseline in the adjusted analysis, with adjusted
mean change of 16.58 (SE, 5.06; P¼ .003) at 1 year after allo-
HCT. Similarly, parent proxyereported HRQoL revealed
higher HRQoL, compared with baseline, 1 year after allo-
HCT, with mean changes of 9.28 (SE, 4.62; P ¼ .05) at 1
year (Table 3).Physical HRQoL
Patients reported a mean physical HRQoL 62.61 (SD,
20.12) at baseline, 66.04 (SD,17.67) at day 180, and 79.79 (SD,
14.65) at 1 year after allo-HCT. The improvement from
baseline was signiﬁcant in the adjusted mixed-effects model
at 1 year, with a mean change of 17.39 (SE, 6.58; P ¼ .015)
(Table 2). Parent proxyereported physical HRQoL improved
over time as well, with a mean physical HRQoL of 68.61 (SD,
20.52) at the baseline, 69.76 (SD, 21.92) at day 180, and 80.00
(SD, 19.03) at 1 year after allo-HCT. The improvement
approached marginal signiﬁcance at 1 year after allo-HCT in
the adjusted model, with an average change of 10.50 (SE,
5.87; P ¼ .083) (Table 3).Social HRQoL
Within the social domain, patients reported a baseline
HRQoL of 72.94 (SD, 15.82), which improved to 75.00 (SD,
20.96) at day 180 before increasing to 86.33 (SD, 19.22) at 1
year after allo-HCT, which was signiﬁcant with a mean
change of 14.0 (SE, 6.25; P ¼ .035) in the adjusted analysis
(Table 2). Within the social domain, baseline parent-reported
HRQoL was 81.52 (SD, 15.33). Parent proxy report indicated
an improvement over time from 81.52 (SD, 15.33) at baseline
to 83.24 (SD, 14.25) at day 180 and 86.50 (SD, 17.93) at 1 year
after allo-HCT (Table 2), though improvements were not
signiﬁcant (Table 3).Emotional HRQoL
Within the emotional domain, the baseline self-reported
mean score was 62.94 (SD, 19.85), which increased to 71.88
(SD, 19.31) at day 180 and 82.00 (SD, 17.09) at 1 year after
allo-HCT, which was a signiﬁcant increase of 19.41 points (SE,
6.66; P ¼ .008) (Table 2). Additionally, the baseline parent
proxyereported scorewas 69.57 (SD,18.70), which improved
to 71.62 (16.43) at day 180 and 81.25 (SD, 18.49) at 1 year
after allo-HCTda signiﬁcant increase of 11.66 points (SE,
5.12; P ¼ .030) in the adjusted model (Table 3).Social HRQoL Emotional HRQoL Psychosocial HRQoL
) 72.94 (15.82) 62.94 (19.85) 67.84 (15.39)
) 75.00 (20.96) (n ¼ 15) 71.88 (19.31) 74.84 (18.27)
86.33 (19.22) 82.00 (17.09) 84.17 (16.89)
1.95 (6.26)
.758
9.10 (6.54)
.177
7.22 (5.77)
.223
14.00 (6.25)
.035z
19.41 (6.66)
.008z
16.78 (5.87)
.009z
eported QOL (adjusted by GVHD, insurance type, and donor source).
Table 3
Parent-Reported HRQoL Scores
Time Overall HRQoL Physical HRQoL Social HRQoL Emotional HRQoL Psychosocial HRQoL
T1: Before HCT* (n ¼ 23 of 23, 100%) 72.20 (15.50) 68.61 (20.52) 81.52 (15.33) 69.57 (18.70) 75.25 (14.83)
T2: 180 Days* (n ¼ 17 of 23, 74%) 73.82 (16.20) 69.76 (21.92) 83.24 (14.25) 71.62 (16.43) 77.08 (14.02)
T3: 365 Days* (n ¼ 20 of 23, 87%) 81.92 (15.63) 80.00 (19.03) 86.50 (17.93) 81.25 (18.49) 83.88 (15.97)
Change over time
T2-T1y
Day 180-baseline
1.57 (4.82)
.747
.69 (6.13)
.912
1.77 (5.14)
.732
2.56 (5.34)
.635
2.12 (4.63)
.650
T3-T1y
Day 365-baseline
9.28 (4.62)
.053
10.50 (5.87)
.083
4.91 (4.93)
.326
11.66 (5.12)
.030z
8.56 (4.44)
.063
* Data presented are mean (SD). Result from adjusted mixed-effect model parent-reported QOL (adjusted by GVHD, insurance type, and donor source).
y Data presented are mean (SE) and P value.
z Indicates statistical signiﬁcance.
Table 4
Selected Results from Group Comparisons at One Year Follow-Up
Insurance
Medicaid Private P Value
n Mean (SD) n Mean (SD)
Self-reported
Overall 4 95.6 (5.7) 11 77.5 (12.8) .007*
Physical 4 93.0 (8.2) 11 75.0 (13.6) .025*
Psychosocial 4 96.9 (6.3) 11 79.5 (17.3) .026*
GVHD
Yes No P Value
n Mean (SD) n Mean (SD)
Self-reported
Emotional 4 65.0 (20.8) 11 88.2 (11.0) .047*
M. Bhatia et al. / Biol Blood Marrow Transplant 21 (2015) 666e672670Psychosocial HRQoL
Lastly, both patient-reported and parent proxyereported
psychosocial health summary scores showed improvements
over time. Patients reported a mean psychosocial HRQoL of
67.84 (SD, 15.39) at baseline, 74.84 (SD, 18.27) at 180 days,
and 84.17 (SD, 16.89) at 1 year after allo-HCT. The improve-
ment from baseline was signiﬁcant at 1 year in the adjusted
model with an increase of 16.78 points (SE, 5.87; P ¼ .009)
(Table 2). Parent proxyereported mean psychosocial HRQoL
was 75.25 (SD, 14.83) at baseline and improved to 77.08
(SD, 14.02) at day 180 and to 83.88 (SD, 15.97) at 1 year after
allo-HCT. The improvement was marginally signiﬁcant in
the adjustedmodel, with an average change of 8.56 (SE, 4.44;
P ¼ .063) (Table 3).
Comparisons of composite ratings between groups
revealed some signiﬁcant disparities based on demographic
and/or clinical variables. On the basis of insurance type,
patients receiving Medicaid reported signiﬁcantly higher
overall (P ¼ .007), physical (P ¼ .025), and psychosocial
(P ¼ .026) HRQoL at 1 year compared with patients with
private insurance. The presence of GVHD also signiﬁcantly
divided groups for both raters. Speciﬁcally, patients who did
not have GVHD reported signiﬁcantly higher psychosocial
(P ¼ .030), social (P ¼ .030), and emotional (P ¼ .047) HRQoL
at 1 year after allo-HCT than those who did have GVHD.
Additionally, parent reporters at 1 year after allo-HCT whose
child did not have GVHD reported signiﬁcantly higher
emotional HRQoL (P ¼ .031) and the parent-reported overall
HRQoL approached signiﬁcance (P ¼ .056) 1 year after
allo-HCT (Table 4).
Pearson correlations were calculated between parent and
patient scores across domains and time points. The greatest
consistency across raters and domains were observed at 1
year after allo-HCT, with signiﬁcant correlations in overall
HRQoL (r¼ .53, P¼ .05), in emotional HRQoL (r¼ .55, P¼ .04),
social HRQoL (r ¼ .59, P ¼ .03), and psychosocial HRQoL
(r ¼ .66, P ¼ .01). The sole exception at 1 year after allo-HCT
was in the domain of physical HRQoL (r ¼ .395, P ¼ .162).
In terms of consistency between parent and self ratings,
ICC were calculated for each scale. ICC values indicated
moderate correlations for overall (ICC ¼ .346) and physical
(ICC ¼ .386) HRQoL, with slightly lower correlations for
emotional (ICC ¼ .296) and psychosocial (ICC ¼ .291) HRQoL.
Analyses also revealed markedly lower consistency on
ratings of social HRQoL (ICC ¼ .141).Social 4 67.5 (27.2) 11 93.2 (10.1) .026*
Psychosocial 4 66.3 (23.3) 11 90.7 (7.8) .030*
Parent-reported
Emotional 4 61.3 (22.5) 16 86.3 (14.1) .031*
Psychosocial 4 69.4 (17.1) 16 87.5 (13.9) .056
* Indicates statistical signiﬁcance.DISCUSSION
This study examined HRQoL in pediatric patients with
SCD after allo-HCT. Speciﬁcally, the design of this study
included 3 serial assessments of patients: before allo-HCTand at 6 months and 12 months after allo-HCT. The mixed
design of this study also allowed for demographic, social, and
clinical variables to be analyzed as possible contributors to
HRQoL ratings, from both self report and parent proxy report.
Self-reported overall baseline HRQoL was lower, falling
below the published at-risk cut off scores for chronically ill
children [19]. This ﬁnding is consistent with prior research
[20,21], which indicates a higher level of distress before allo-
HCT, likely caused by physical symptoms and anxiety asso-
ciated with the anticipated treatment. Self-reported HRQoL
ratings subsequently exceeded the chronically ill population
after allo-HCT and signiﬁcantly improved over time by 1 year
after allo-HCT within the domains of overall, physical,
emotional, and psychosocial functioning, reﬂecting the
length of time required to evidence signiﬁcant improvement.
Of note, social HRQoL was the sole domain that did not
signiﬁcantly improve from baseline by 1 year after allo-HCT.
Similarly, parent proxy reports indicated overall HRQoL was
lower than the population mean for chronically ill children;
however, higher HRQoL were reported after allo-HCT, with
signiﬁcant change noted within the domains of overall,
emotional, and psychosocial functioning by 1 year after allo-
HCT. Of note, physical HRQoL was the only domain that did
not signiﬁcantly improve at 1 year after allo-HCT by parent
proxy report. These observed improvements in HRQoL may
be related to the emerging trend that childrenwith SCD who
receive allo-HCT require signiﬁcantly fewer inpatient visits
by 1 year after allo SCT compared with children with SCD
who did not undergo transplantation, as well as requiring
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alloSCT [22].
With regard to physical HRQoL, patients reported
signiﬁcantly higher scores at 1 year after allo-HCT, whereas
parent proxies did not report signiﬁcantly higher scores,
though their ratings approached signiﬁcance at 1 year after
allo-HCT. It appears that patients are experiencing
improved physical functioning that may not be as readily
apparent to their caregivers or that the patients are over-
estimating their physical functioning. Caocci et al. [23]
suggests that differences in perception between pediatric
patients and parents may be related to parental stress in the
post-HCT period, as the child’s clinical condition tends to be
more guarded in this phase. In contrast, parental percep-
tions may be supported by prior ﬁndings that measure-
ments of physical functioning in survivors years after HCT
reveal impairments that are signiﬁcantly worse than
healthy controls, as well as lower than what self report and
clinician data indicate [24,25]. Given that the lowest Pear-
son correlation among the HRQoL areas at 1 year was within
the domain of physical functioning, more subjective and
objective measurement data are required to better under-
stand the trajectory of physical functioning recovery after
transplantation, which can inform opportunities for pro-
active physical therapy interventions.
Patients and parent proxies reported improvements in
emotional HRQoL after transplantation, which is consistent
with previous ﬁndings of patients reporting satisfactory
psychological functioning as far as 2 years after HCT [26],
although complications by demographic variables have been
reported [27]. Interestingly, the pattern of patient endorse-
ment of higher levels of emotional symptoms than their
parents report and the above-mentioned lower correlation
between patient and parent on physical functioning are both
inconsistent with prior studies indicating higher concor-
dance between patient and proxy reports of HRQoL in
observable domains (eg, the presence of somatic symptoms
or level of physical functioning) than in more subjective
phenomena (eg, psychological distress) [28,29].
With regard to social HRQoL, although improvements in
mean scores were noted, patient and parent proxies both did
not report signiﬁcantly improved social HRQoL within the
ﬁrst year. In fact, this is the only domain inwhich patients did
not report a signiﬁcant improvement by 1 year after trans-
plantation. Current research in the ﬁeld suggests social
functioning tends to decline within the ﬁrst year after
transplantation before improving [21,26]. Although patients
understandably experience social isolation during and
immediately after treatment, the continued feelings of social
isolation after allo-HCT represent an important area for
intervention by psychosocial clinicians working with this
population. This phenomenon is probably best understood in
large part by the medical treatment protocol guidelines for 1
year of isolation after transplantation. As mentioned previ-
ously, patients were not yet re-enrolled in school by this
time, which may contribute to their functioning across do-
mains, particularly for their social HRQoL ratings. Specif-
ically, the development of interventions that assist patients
to maintain social connections during and immediately after
allo-HCT, perhaps through online or social media including
technology to join classrooms and staying connected with
peers could be very beneﬁcial. The psychosocial summary
score measured HRQoL across the combined social and
emotional scales. Similar to the patterns observed in most
individual domains, self- and parent proxyereportedpsychosocial HRQoL reached signiﬁcant levels of improve-
ment at 1 year after allo-HCT.
Additional analyses included demographic and medical
data, investigating group differences by demographic vari-
ables such as insurance type, presence or absence of GVHD,
allogeneic type, and hematopoietic cell source. Researchers
commonly observe the impact of clinical [23,24,26] and de-
mographic [27] variables, such as GVHD and insurance type
on HRQoL. In the current study, the presence of focal
signiﬁcant interactions were observed only at the 1-year
follow-up, involving lowered self-reported HRQoL within the
domains of overall, physical, and psychosocial HRQoL for
those with private insurance, in addition to lowered self-
reported HRQoL within the domains of emotional, social,
and psychosocial for those who developed GVHD. It is
interesting to note that a singular signiﬁcant interaction by
parent report was observed in the domain of emotional
HRQoL for children who were diagnosed with GVHD. These
ﬁndings support the importance of obtaining self-report
HRQoL, which can provide a distinct and equally important
perspective, as well as the appreciation of the amount of time
it can require for signiﬁcant differences to emerge. Although
the ﬁndings based upon the presence of GVHD are under-
standable, given the discomfort and additional medications
required, the disparities based upon insurance type raises
more questions than answers. Clearly, future studies should
explore the impact of socio-economic status on long-term
HRQoL within this population, as well as to more fully
understand the pretransplantation quality of life and the
speciﬁc expectations of the transplantation for patients and
parents.
Limitations of this study include the small sample size,
although it is signiﬁcantly larger than the only other pub-
lished study with this population. The sample also has
missing values at different points for different subjects,
which may signiﬁcantly affect sample size, depending on
how the mixed linear model addresses missing data.
Consequently, all nonmissing values were included inmixed-
effects model; however, the issue of missing values could
remain a limitation because of our limited small sample size.
Additionally, all data were collected from a single institution,
which may limit the generalizability of the data; however,
this perhaps can simultaneously provide the advantage of
offering a more uniform study population and treatment
regimen. Future studies would beneﬁt from multisite data
collection, as there is variation among individual centers’
practice guidelines, such as return to school and activity re-
strictions that could clearly impact HRQoL. Finally, the racial
and ethnic composition of this sample, 56.5% Hispanic and
39.1% African American, is incongruent with the distribution
of SCD at large. Because the prevalence of SCD is much
greater in African American populations compared with
Hispanic and other racial/ethnic groups [30], the ﬁndings of
the current study may be somewhat more generalizable to
the Hispanic population.
Future studies into the HRQoL of patients with SCD would
also beneﬁt from the inclusion of the PedsQL SCD module
[31] to better understand the impact of the disease over time,
as well as to detect differences between different levels of
severity of SCD and other chronic illnesses. This approach
may be particularly informative as it relates to integral de-
mographic variables (eg, socioeconomic status, gender,
ethnicity, etc.), as well as medical variables, such as the
impact of GVHD and type of transplantation, upon HRQoL in
larger samples. Furthermore, given a paramount sequelae of
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fatigue, which has not been systematically assessed or
reported in the literature, the PedsQL Multidimensional
Fatigue Scale [32] can add much needed depth to our
understanding of the clinical manifestations of the disorder.
CONCLUSIONS
These results suggest that, in addition to the improvement
inphysical symptoms seen inpatientswithSSDafterallo-HCT,
the general improvement in HRQoL over time is encouraging
and represents another factor for families and caregivers to
consider before deciding upon stem cell transplantation in
select patients with SCD. These ﬁndings may simultaneously
guide the development of proactive interventions, particu-
larly within the acute post-transplantation phase, to assist
children in adjusting to their newly emerging medical iden-
tities (ie, fewer emergent visits to the hospital, fewer oppor-
tunities for interaction with supportive clinic staff, while at
the same time not being allowed to return to school or social
activities for up to 1 year after allo-HCT). Overall, this study
highlights the signiﬁcant improvement in the overall, psy-
chosocial, and emotional HRQoL by both self and parent
report, along with signiﬁcant improvement in the physical
HRQoL by self report. These results may assist families when
considering allo-HCT as a treatment for SCD [33].
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